Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC

Dr Christina Baik - University of Washington School of Medicine, Seattle, USA

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in...

Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

IMpower010: Atezolizumab versus best supportive care after adjuvant...

Prof Heather Wakelee - Stanford University, Stanford, USA

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC ( Prof Heather Wakelee - Stanford University, Stanford, USA )

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival...

Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes ( Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA...

Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )

Adjuvant chemo following chemoradiation as treatment for locally advanced...

Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia

Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone ( Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia )

Tislelizumab in oesophageal cancer after systemic therapy

Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA

Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with...

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

More from ecancer